12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology ... data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO ...

The TATX-112 program, dedicated to the development of specialized antibodies for cancer treatment, has shown encouraging results, successfully targeting cells that express a protein known as TrkB.

[68,69] Doxycycline (a tetracycline) was shown to inhibit superantigen-induced T-cell proliferation and cytokine and chemokine production by PMN cells ... First, antibodies (i.e., secretory ...

The new kits enable researchers to profile the mouse BCR repertoire alongside whole transcriptome data for millions of cells in a single experiment, offering unmatched scale and efficiency for ...